Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial.
OBJECTIVE
To compare neurodevelopmental outcome of survivors of the multicentre trial of etamsylate (the iRNN for ethamsylate) for prevention of periventricular haemorrhage in very low birthweight infants.


METHODS
Double blind, single observer, prospective follow up of placebo controlled study.


METHODS
Six neonatal intensive care units in the United Kingdom. Neurodevelopmental outcome was assessed in health premises or children's homes.


METHODS
268 of 276 survivors of the original study were seen between 3.5 and 4.2 years of age. All were inborn and weighed 1500 g or less at birth.


METHODS
Etamsylate 12.5 mg/kg or placebo six hourly from within one hour of delivery for four days.


METHODS
McCarthy scales of children's abilities, standardised neurological examination, full physical examination, functional assessment, seven letter Stycar vision test, and audiometry.


RESULTS
There was no difference between the groups in neuromotor outcome (cerebral palsy) or in the general cognitive index (GCI) of the McCarthy scales (mean GCI was 93.3 for the etamsylate group (n = 133) and 89.7 for the placebo group (n = 131); p = 0.10). There were more children with GCI < 70 (9 v 19; p = 0.047) or </= 50 (3 v 11; p = 0.03) in the placebo group. Fewer children in the etamsylate group had squints (17 v 30; p = 0.042) or required surgery for patent ductus arteriosus (1 v 8; p = 0.036).


CONCLUSIONS
Etamsylate was not associated with a reduction in cerebral palsy. Severe cognitive impairment was reduced, but more children died and the improvement may be because fewer survived with low GCI.
Schulte
J
J
Royal United Hospital, Combe Park, Bath BA1 3NG, UK.
Osborne
J
J
Benson
J W T
JW
Cooke
R
R
Drayton
M
M
Murphy
J
J
Rennie
J
J
Speidel
B
B
D002543:Cerebral Hemorrhage / Q000517:prevention & control*; D002547:Cerebral Palsy / Q000517:prevention & control; D002657:Child Development / Q000187:drug effects*; D003072:Cognition Disorders / Q000517:prevention & control; D004311:Double-Blind Method; D004979:Ethamsylate / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D008297:Male; D016896:Treatment Outcome
D006490:Hemostatics; D004979:Ethamsylate